Insulinomas have long posed a significant clinical challenge due to their unpredictable behavior and the severe hypoglycemia they induce through uncontrolled insulin release. Traditional diagnostic tools and treatments have faced limitations in effectively targeting the molecular mechanisms responsible for these tumors’ relentless hormonal output. The recent studies conducted by the team at the Institute of Science Tokyo delve deep into the genetic landscape of insulinomas, utilizing cutting-edge technologies that combine surgical specimen analysis with patient-derived organoid models.

Central to the investigation was the DOCK10 gene, a member of the dedicator of cytokinesis family, known for its role in modulating cell morphology and signal transduction pathways. Through comprehensive genetic and transcriptomic profiling, researchers uncovered that DOCK10 expression is substantially upregulated in insulinoma tissues compared to normal islet cells. This overexpression correlates strongly with heightened insulin secretion, suggesting a causal relationship.

To unravel the mechanistic pathways, the team employed patient-derived insulinoma organoids—three-dimensional cell cultures that accurately mimic the tumor microenvironment. These organoids allowed for meticulous functional studies, revealing that DOCK10 influences insulin release by modulating specific intracellular signaling cascades linked to vesicular trafficking and secretion. Notably, the aberrant activity of DOCK10 alters cytoskeletal dynamics, which play a critical role in the insulin secretory pathway.

Intriguingly, the researchers pinpointed a downstream effector pathway connected to DOCK10 activity. Pharmacological inhibition targeting this pathway in both cellular and animal models yielded a marked reduction in the excessive insulin secretion characteristic of insulinomas. This discovery is monumental because it transitions DOCK10 from a mere biomarker to a viable therapeutic target, paving the way for precision medicine tailored to halt pathological insulin release.

The study’s methodological rigor combined next-generation sequencing technologies with advanced bioinformatics to decode the complex gene expression profiles that define insulinoma cells. These data were then integrated with functional assays that assessed insulin granule dynamics and secretion rates, establishing a robust link between DOCK10 expression and insulin exocytosis.

From a clinical perspective, these findings unlock the potential for improved diagnostics. The upregulation of DOCK10 could serve as a biomarker to distinguish insulinomas from other pancreatic neuroendocrine tumors, which is crucial given the diverse clinical behaviors and treatment responses among these neoplasms. Additionally, monitoring DOCK10 levels might aid in tracking disease progression or recurrence post-surgery.

Furthermore, the development of inhibitors targeting the DOCK10-associated pathway offers a promising therapeutic strategy. Unlike general anti-insulin secretion drugs that risk impairing normal pancreatic function, selective inhibition of DOCK10 pathways could suppress pathological insulin secretion without compromising basal insulin levels, minimizing side effects.

This investigation also emphasizes the power of patient-derived organoids in cancer research. These models faithfully recapitulate individual tumor biology, allowing researchers to screen targeted agents effectively before clinical translation. The ability to test DOCK10 inhibitors on patient-specific tumor models accelerates personalized medicine approaches, potentially shortening the timeline from bench to bedside.

Beyond immediate clinical implications, the elucidation of DOCK10’s role in insulin secretion challenges existing paradigms of pancreatic tumor biology. It raises questions about the contribution of cytoskeletal regulators in hormone secretion disorders and encourages reevaluation of similar pathways in other neuroendocrine tumors.

The research team plans to extend their investigations by conducting clinical trials assessing DOCK10 pathway inhibitors’ safety and efficacy in humans. Moreover, longitudinal studies will determine whether DOCK10 expression levels correlate with patient outcomes, including response to surgery and recurrence risk.

In summary, the identification of DOCK10 as a key driver of abnormal insulin secretion revolutionizes our approach to insulinomas. By combining sophisticated genetic analyses, functional modeling, and pharmacological interventions, this study provides a comprehensive framework to diagnose, monitor, and treat insulinoma patients more effectively. The implications of this work reverberate beyond insulinomas, offering new insights into neuroendocrine tumor biology and therapeutic innovation.

The findings from the Institute of Science Tokyo mark a significant leap forward in combating one of the most enigmatic and challenging pancreatic tumors. With continued research and clinical validation, targeting the DOCK10 pathway could soon become a cornerstone of personalized therapy, offering hope for patients with insulinomas worldwide.

Subject of Research: Insulinomas and the genetic mechanisms driving abnormal insulin secretion

Article Title: DOCK10 Identified as a Key Driver of Aberrant Insulin Secretion in Insulinomas

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Institute of Science Tokyo (via EurekAlert)

Keywords: DOCK10, insulinoma, insulin secretion, pancreatic neuroendocrine tumors, gene expression, organoids, targeted therapy, hormone secretion, molecular pathway, neuroendocrine tumors, personalized medicine, tumor biomarkers

The challenge in treating CRPC-NE lies in its aggressive nature and diminished dependence on androgen receptor signaling—a pathway conventional therapies target. Tumors frequently circumvent AR blockade by adopting neuroendocrine phenotypes, which no longer respond to AR inhibitors like enzalutamide, leading to poor clinical outcomes. Through sophisticated genetic manipulation of patient-derived organoid models, the research team demonstrated that ablating NSD2 reactivates AR expression and reinstitutes tumor vulnerability to enzalutamide, offering a novel method to overcome therapeutic resistance.

In an extensive series of experiments, NSD2 was inactivated via CRISPR-Cas9 mediated gene knockout in neuroendocrine prostate cancer organoids. Remarkably, this intervention reinstated AR protein levels that had previously been downregulated in CRPC-NE states. Employing dose–response assays, the investigators observed a significant reduction in organoid growth upon treatment with enzalutamide post-NSD2 targeting, with half-maximal inhibitory concentrations (IC50) plummeting below 3 micromolar. This quantitative shift underscored a dramatic re-sensitization of cancer cells to androgen deprivation therapies.

Extending these findings to in vivo models, the team employed subcutaneous grafting of both NSD2-deficient and control organoids into immunodeficient NOD/SCID mice. Upon reaching a critical tumor size, animals were treated with enzalutamide or vehicle control. Tumors lacking NSD2 exhibited significantly impaired growth under androgen blockade, while controls continued to proliferate unabated. Histological examination revealed a profound phenotypic switch; loss of neuroendocrine markers coupled with decreased proliferation indices such as Ki67 and resurgence of adenocarcinoma characteristics highlighted epigenetic reversion towards a more canonical prostate cancer state.

Parallel experiments utilizing human-derived MSKPCa10 organoids substantiated the translational relevance of these findings. NSD2 knockout in these human cells similarly restored responsiveness to enzalutamide both in vitro and in xenograft models, suggesting a conserved mechanism linking NSD2 activity to drug resistance across species. This critical validation establishes NSD2 as a viable target for clinical intervention in therapy-refractory prostate cancers.

Mechanistic insights at the molecular level revealed that NSD2 depletion triggers a global reprogramming of androgen receptor signaling. The expression of classical AR target genes showed robust enrichment post-NSD2 targeting, an effect confirmed at single-cell resolution. Notably, NSD2-deficient organoids manifested a proliferative response to the AR agonist dihydrotestosterone (DHT), which was absent in controls—indicating a restoration of functional AR signaling capable of modulating tumor cell growth.

This study situates NSD2 as a central epigenetic effector that governs phenotypic plasticity in prostate cancer, facilitating the shift from AR-dependent adenocarcinoma to neuroendocrine phenotypes upon which standard therapies fail. By reversing this epigenetic switch, NSD2 inhibition reinstates the canonical AR transcriptional program, reversing resistance and sensitizing tumors to enzalutamide. These findings unlock new paths for targeted epigenetic therapy, potentially combining NSD2 inhibitors with existing AR antagonists to overcome resistance mechanisms.

Furthermore, the work highlights the utility of patient-derived organoids as powerful preclinical platforms enabling precise genetic editing and pharmacological testing. This approach allows real-time evaluation of molecular dependencies within heterogeneous cancer cell populations, accelerating the discovery of context-specific vulnerabilities. The successful translation of organoid-based results into in vivo murine models strengthens the potential for rapid clinical application.

Overall, this paradigm-changing research advances our understanding of molecular determinants underpinning prostate cancer evolution and therapy resistance. It underscores the intricate interplay between epigenetic modifiers and hormonal signaling pathways, offering hope for more durable and effective interventions against metastatic prostate cancer. With further development, NSD2 targeting could usher in a new era of precision epigenetic therapies complementing androgen receptor blockade.

The promising results prompt urgent exploration into the development of selective NSD2 inhibitors suitable for clinical use. Future investigations will be crucial to unravel potential off-target effects, establish optimal dosing regimens, and assess therapeutic windows when combined with enzalutamide. Given the dire prognosis associated with CRPC-NE, this line of research may significantly extend survival and improve quality of life for affected patients.

In light of these discoveries, integrating epigenetic modulation strategies into standard prostate cancer treatment algorithms appears an auspicious direction. The elucidation of resistance reversal mechanisms by NSD2 loss provides a conceptual blueprint for tackling the heterogeneity and adaptability that have so far confounded durable responses in late-stage disease. As research progresses, the prospect of overcoming the deadliest phenotypes of prostate cancer moves closer to reality.

These breakthroughs also raise compelling questions about the broader role of epigenetic regulators in cancer plasticity and drug resistance beyond prostate cancer. By exploiting similar vulnerabilities in other malignancies exhibiting lineage plasticity, targeted NSD2 inhibition or analogous epigenetic reprogramming might enhance responsiveness to a variety of existing therapies. This study therefore opens avenues of translational potential across oncology.

In conclusion, the identification of NSD2 as a pivotal regulator of therapeutic plasticity and resistance in neuroendocrine prostate cancer represents a milestone in cancer epigenetics and precision medicine. The restoration of enzalutamide sensitivity via NSD2 targeting reveals actionable vulnerabilities that can be leveraged to design revolutionary treatment combinations. This paradigm shift affords renewed hope for patients battling drug-resistant prostate cancer and exemplifies the power of integrating genetic and epigenetic insights to surmount clinical challenges.

Subject of Research: Epigenetic regulation and therapeutic resistance in neuroendocrine prostate cancer

Article Title: NSD2 targeting reverses plasticity and drug resistance in prostate cancer

Article References:
Li, J.J., Vasciaveo, A., Karagiannis, D. et al. NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Nature (2025). https://doi.org/10.1038/s41586-025-09727-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09727-z